modul
proteolyt
activ
import
factor
regul
metabol
function
peptid
hormon
studi
activ
dipeptidyl
carboxi
peptidas
angiotensinconvert
enzym
ace
aminopeptidas
n
apn
dipeptidyl
amino
peptidas
iv
dpp
iv
measur
blood
human
bronchial
epitheli
alveolar
cell
bronchoalveolar
macrophag
solubl
phase
bronchoalveolar
lavag
bal
sampl
obtain
normal
human
volunt
patient
pulmonari
patholog
condit
bal
fluid
express
ace
activ
low
level
apn
dpp
iv
activ
volunt
popul
higher
level
could
measur
sampl
patient
patient
increas
apn
correspond
high
granulocyt
count
dpp
iv
ace
associ
high
percentag
lymphocyt
neither
aid
smoke
induc
increas
level
enzym
immunohistochem
stain
bronchoalveolar
smear
antihuman
ace
monoclon
antibodi
show
macrophag
express
enzym
enzym
histochemistri
dpp
iv
apn
show
leukocyt
express
activ
apn
dpp
iv
ace
activ
also
found
cell
extract
bronchoalveolar
macrophag
extract
bronchial
epitheli
alveolar
cell
apn
dpp
iv
activ
detect
kinet
properti
solubl
enzym
lavag
supernat
compar
serum
enzym
result
demonstr
solubl
form
cellular
enzym
found
bal
fluid
regul
independ
blood
differ
cell
type
may
releas
enzym
j
lab
clin
med
abbrevi
ace
angiotensinconvert
enzym
aid
acquir
immunodefici
syndrom
apn
ominopeptidas
n
bal
bronchoalveolar
lavag
dpp
iv
dipepfidyl
amino
peptidas
iv
gtp
yglutamyltranspeptidas
hiv
human
immunodefici
viru
inhibitori
concentr
k
michaelismenten
constant
pb
phosphatebuff
salin
solut
z
benzyloxycarbonylproteolyt
enzym
involv
activ
transform
degrad
protein
peptid
hormon
variou
regulatori
pathway
process
peptid
antigen
present
immunocompet
cell
degrad
extracellular
matrix
thu
tight
control
proteas
activ
necessari
maintain
normal
cell
function
proteolyt
process
hormon
particular
enzym
may
modul
biolog
function
peptid
hormon
often
process
sever
differ
proteas
depend
access
enzym
specif
hormon
presenc
substanc
modul
proteas
activ
membranebound
solubl
proteas
may
differ
enzymat
potenc
differ
access
peptid
function
rel
locat
peptid
enzym
sever
cell
surfac
antigen
defin
leukocyt
differenti
marker
shown
proteolyt
enzym
also
express
epithelium
endothelium
tissu
demonstr
leukocyt
differenti
impli
modul
proteas
express
howev
factor
involv
differenti
phenomena
well
understood
patholog
condit
apnbut
dpp
ivi
specif
express
mononuclear
cell
activ
alveolar
macrophag
differenti
stimul
express
cathepsin
apn
hiv
infect
also
modifi
proteolyt
activ
epitheli
cell
mononuclear
phagocyt
lymphocyt
abl
express
secret
mani
hydrolyt
enzym
well
inhibitor
although
inform
gain
proteaseantiproteas
imbal
lung
emphysema
regul
peptidas
involv
metabol
small
peptid
extens
evalu
pulmonari
bronchoalveolar
space
present
studi
enzymat
activ
two
aminopeptidas
apn
dpp
iv
dipeptidyl
carboxi
peptidas
ace
measur
solubl
enzym
bal
fluid
cellbound
enzym
human
bronchial
epitheli
cell
nontumorigen
cell
line
phenotyp
close
bronchial
cell
alveolar
epitheli
cell
cell
deriv
alveolar
type
ii
carcinoma
atcc
bronchoalveolar
macrophag
enzym
evalu
human
bal
fluid
obtain
normal
human
male
volunt
patient
variou
lung
disord
compar
cellular
reparfit
macrophag
granulocyt
lymphocyt
studi
subject
bal
perform
nonsmok
male
volunt
subject
select
thorough
questionnair
clinic
examin
exclud
past
present
ill
well
take
medic
addit
pulmonari
function
test
perform
subject
abnorm
spirometri
posit
methacholin
challeng
test
exclud
nonsmok
bal
patient
underw
bronchoscopi
diagnost
purpos
also
retrospect
analyz
patient
popul
repres
variou
patholog
condit
includ
tumor
sarcoidosi
infecti
diseas
aid
studi
protocol
normal
volunt
approv
ethic
committe
institut
formal
request
made
bal
analysi
patient
group
part
studi
retrospect
bal
done
primarili
diagnost
purpos
bal
sampl
prepar
bronchoscopi
perform
normal
nonsmoldng
subject
patient
accord
standard
procedur
steril
salin
solut
ml
inject
ml
aliquot
via
fiber
optic
bronchoscop
aspir
filter
steril
gauz
volunt
lavag
done
exclus
subseg
right
middl
lobe
recoveri
time
contact
inject
liquid
may
import
paramet
influenc
result
paramet
maintain
standard
fashion
possibl
volunt
studi
total
recov
cell
differenti
cell
count
determin
aliquot
sampl
treat
cell
cultur
remain
cell
fluid
separ
centrifug
aliquot
supernat
frozen
c
volunt
studi
macrophag
isol
adhes
plastic
hour
rpmi
gibco
medium
contain
fc
differenti
cell
count
perform
concentr
filtrat
millipor
ixm
smwp
membran
hematoxylinlight
green
giemsa
stain
enzymat
activ
measur
pl
apn
dpp
iv
ace
supernat
describ
blood
withdrawn
time
lavag
volunt
studi
aliquot
serum
frozen
six
broad
disord
categori
defin
follow
sarcoidosi
stage
diagnos
lung
biopsi
characterist
bal
cellular
profil
interstiti
pneumopathi
origin
diagnosi
sarcoidosi
reason
exclud
pulmonari
infect
immunocompet
patient
pulmonari
infect
hivposit
patient
stage
primari
secondari
lung
neoplasm
blood
malign
myeloid
lymphoid
lineag
cell
cultur
cell
obtain
dr
c
c
harri
nation
cancer
institut
bethesda
md
grown
collagen
fibronectin
albuminco
flask
serumfre
medium
describ
cell
atcc
grown
rpmi
medium
contain
fetal
calf
serum
gibco
reach
confluenc
cell
wash
twice
pb
detach
pb
rubber
policeman
lyse
cycl
sonicationfreez
adher
macrophag
normal
volunt
treat
cell
cultur
enzymat
activ
measur
ixl
apn
dppiv
ace
cell
extract
describ
aminopeptmas
activ
situ
enzymat
activ
aliquot
bal
cell
suspens
concentr
centrifng
onto
glass
slide
cytocentrifug
incub
minut
c
bachem
substrat
apn
dpp
iv
respect
final
concentr
mmolfl
pb
buffer
mmoll
fast
blue
bb
sigma
previous
describ
solubl
enzymat
determin
leuand
glyprop
macrophagespecif
monoclon
antibodi
commerci
sourc
dako
use
dilut
antihuman
ace
monoclon
antibodi
gift
sm
danilov
inserm
pari
character
antibodi
describ
lyophil
antibodi
dissolv
water
mgml
use
dilut
pb
bal
cell
concentr
centrifug
smear
prepar
smear
fix
paraformaldehyd
wash
pb
block
minut
normal
goat
serum
incub
overnight
c
primari
antibodi
peroxidaseconjug
secondari
goat
antimous
immunoglogulin
dako
ad
minut
follow
addit
diaminobenzidin
control
slide
primari
antibodi
omit
statist
evalu
result
express
mean
sem
statist
signific
assess
calcul
correl
coeffici
r
twotail
unpair
student
test
oneway
analysi
varianc
follow
bonferroni
posttest
correct
comparison
normal
volunt
select
patholog
state
nonparametr
kruskalw
test
use
follow
dunn
q
analysi
applic
studi
normal
male
volunt
collect
randomli
select
frozen
bal
sampl
retrospect
studi
without
preliminari
select
patient
patholog
state
analysi
collect
known
smoker
nonsmok
patient
aid
select
addit
select
patient
welldocu
diagnost
avail
specif
analyz
clinic
data
normal
volunt
select
patient
summar
tabl
cell
repartit
macrophag
lymphocyt
polymorphonuclear
neutrophil
within
normal
valu
normal
volunt
bal
supernat
obtain
normal
volunt
tabl
ii
patient
variou
patholog
condit
tabl
iii
specif
express
ace
apn
dpp
iv
activ
patient
popul
dipeptidas
activ
hisleu
control
ensur
low
level
ace
activ
caus
hisleu
degrad
tabl
iii
compar
ace
apn
dpp
iv
kinet
properti
bal
fluid
plasma
effect
specif
inhibitor
lisinopril
actinonin
diprotin
respect
analyz
lisinopril
inhibit
enzymat
activ
solubl
ace
two
bal
two
blood
sampl
fig
respect
valu
rtmoll
enzym
blood
txmoll
enzym
bal
fluid
howev
k
valu
mmoll
measur
control
cf
concentr
xaxi
intercept
lineweav
burk
plot
substrat
inhibit
start
mmoll
substrat
concentr
characterist
mani
carboxypeptidas
includ
ace
ident
enzym
blood
bronchoalveolar
origin
amount
inhibitor
necessari
inhibit
half
activ
serum
bal
ace
activ
higher
postul
inhibit
constant
explain
high
substrat
concentr
necessari
evalu
ace
vitro
shown
inhibit
decreas
high
sk
ratio
ace
activ
serum
bal
supernat
n
r
bal
supernat
bal
cell
extract
n
r
normal
volunt
correl
patient
popul
solubl
ace
activ
increas
lymphocyt
content
bal
increas
p
tabl
iv
independ
number
granulocyt
actinonin
diprotin
similarli
inhibit
blood
bal
enzym
fig
b
apn
activ
inhibit
actinonin
bal
fluid
uml
serum
uml
fig
dpp
iv
activ
inhibit
diprotin
bal
fluid
uml
serum
uml
fig
b
valu
p
moll
txmoll
respect
patient
popul
solubl
apn
activ
markedli
elev
rel
proport
granulocyt
increas
tabl
iv
dpp
iv
slightli
elev
increas
proport
lymphocyt
observ
tabl
iv
independ
number
granulocyt
wherea
activ
measur
sampl
normal
cellular
repartit
howev
strict
correl
bal
cellular
composit
supernat
enzym
activ
could
observ
bal
fluid
contain
determin
two
normal
serum
sampl
two
lavag
supernat
preincub
minut
decreas
concentr
lisinopril
substrat
ad
ace
activ
determin
describ
b
k
determin
decreas
concentr
zphehisleu
ad
either
two
normal
serum
sampl
two
supernat
bal
ace
activ
measur
arrow
indic
substrat
inhibit
high
proport
either
granulocyt
lymphocyt
activ
apn
ace
dpp
iv
elev
sampl
high
level
enzymat
activ
respect
proport
correspond
cell
increas
sampl
high
level
apn
actmti
also
express
increas
level
dpp
iv
sampl
one
enzymat
activ
elev
thu
rel
proport
even
absolut
number
three
class
cell
evalu
exclus
factor
determin
rel
level
enzymat
activ
undetermin
factor
like
involv
examin
potenti
clinic
relev
factor
evalu
sever
distinct
group
clinic
data
tabl
disord
fig
b
c
patient
sarcoidosi
fig
group
b
significantli
elev
level
ace
activ
elev
level
enzym
also
found
patient
blood
malign
fig
group
g
normal
level
ace
activ
found
pulmonari
disord
includ
interstiti
pneumopathi
sarcoidosi
exclud
infect
neoplasia
group
c
f
comparison
made
normal
volunt
group
specif
condit
could
found
patient
ace
activ
valu
normal
rang
apn
activ
increas
sampl
pulmonari
infect
fig
b
group
e
dpp
iv
activ
sampl
group
except
sampl
patient
blood
malign
fig
c
bal
sampl
small
group
patient
sarcoidosi
n
apn
activ
found
normal
rang
uml
wherea
dpp
iv
activ
increas
uml
accord
result
obtain
high
lymphocyt
count
tabl
iv
analyz
effect
two
known
modul
immun
system
effect
aid
patholog
current
smoke
cigarett
per
day
evalu
tabl
v
conclud
neither
condit
alon
importantli
alter
level
proteolyt
enzym
studi
howev
smoker
exhibit
lower
ace
activ
bal
fluid
compar
nonsmok
p
aminopeptidas
activ
evalu
situ
cell
bal
apn
dpp
iv
fig
b
detect
immunohistochem
stain
monoclon
antiac
antimacrophag
antibodi
demonstr
ace
express
bronchoalveolar
macrophag
fig
howev
number
cell
stain
posit
ace
smear
correl
ace
activ
cell
extract
result
shown
ace
immunostain
also
observ
exclus
macrophag
bronchoalveolar
cell
obtain
sampl
high
lymphocyt
ratio
macrophag
lymphocyt
shown
human
epitheli
cell
bronchial
alveolar
origin
express
apn
dpp
iv
activ
well
ygtp
specif
marker
epitheli
cell
use
intern
control
ace
activ
bal
macrophag
express
apn
dpp
iv
ace
activ
gtp
activ
tabl
vi
role
membranebound
proteas
well
understood
might
link
hormon
metabol
possibl
cell
adhes
migrat
proteas
shed
membran
regulatori
mechan
degrad
peptid
biolog
fluid
regul
cell
adhes
membranebound
proteas
although
activ
small
synthet
substrat
effici
larger
natur
peptid
substrat
better
hydrolyz
enzym
releas
membran
regul
proteas
involv
metabol
peptid
hormon
bronchoalveolar
space
extens
evalu
normal
situat
lung
disord
express
peptidas
either
pulmonari
cell
supernat
bal
previous
shown
enzym
exampl
rat
model
carboxypeptidas
neutral
endopeptidas
releas
bal
fluid
howev
evalu
enzym
activ
bronchoalveolar
cell
supernat
blood
normal
human
studi
perform
ace
result
demonstr
ace
apn
dpp
iv
secret
human
epitheli
line
fluid
solubl
enzym
express
specif
cell
bronchoalveolar
surfac
macrophag
ace
apn
dpp
iv
epitheli
cell
apn
dpp
iv
absenc
correl
ace
enzymat
activ
bal
supernat
blood
normal
situat
suggest
independ
regul
biolog
compart
confirm
high
level
apn
dpp
iv
activ
measur
normal
situat
blood
almost
undetect
activ
bal
fluid
normal
volunt
patient
activ
ace
detect
sampl
howev
activ
apn
dpp
iv
low
normal
situat
dramat
increas
patholog
sampl
ace
ec
ubiquit
membranebound
ectopeptidas
wide
specif
abl
remov
dipeptid
tripeptid
without
process
carboxyl
end
protein
potenti
substrat
includ
bradykinin
substanc
p
angiotensin
enkephalin
use
ace
inhibitor
treatment
hypertens
sometim
link
cough
possibl
increas
bronchial
reactiv
decreas
degrad
enzym
proinflammatori
peptid
bradykinin
substanc
interestingli
found
lower
ace
activ
bal
fluid
smoker
group
ace
involv
bradykinin
degrad
might
potenti
import
implic
effect
smoke
peptid
metabol
serum
ace
activ
increas
activ
sarcoidosi
hiv
hyperthyroid
find
increas
level
enzym
bal
fluid
patient
hiv
confirm
differenti
regul
enzym
compart
level
ace
activ
significantli
increas
sampl
high
lymphocyt
count
bal
patient
sarcoidosi
confirm
previou
result
lymphoid
neoplasm
new
find
normal
sampl
ace
antigen
express
macrophag
sever
cellsurfac
antigen
cluster
differenti
system
emerg
cellsurfac
peptidas
wide
distribut
dpp
iv
ec
peptidas
specif
releas
xaa
pro
xaaala
dipeptid
ntermin
end
peptid
analog
dpp
involv
cell
activ
mainli
cell
vivo
vitro
also
express
epithelia
certain
endothelia
platelet
express
dpp
iv
shown
bronchoalveolar
macrophag
cell
present
studi
found
low
level
dpp
iv
activ
cell
line
cell
discrep
may
explain
differ
method
dosag
differ
confluenc
cultur
found
express
dpp
iv
activ
depend
cell
confluenc
variou
epitheli
cell
line
unpublish
experi
number
cell
decreas
hiv
infect
howev
activ
dpp
unchang
blood
patient
observ
lack
relationship
bal
fluid
dpp
iv
activ
slightli
increas
independ
presenc
peli
fig
immunocytochem
stain
ace
bronchoalveolar
cell
smear
comparison
ace
activ
cell
extract
normal
volunt
histochem
stain
bronchoalvelar
cell
smear
acespecif
monoelon
antibodi
use
experi
b
ident
cell
control
macrophagespecifi
antibodi
c
neg
control
obtain
without
primari
antibodi
morphonuclear
cell
lymphocyt
proport
increas
bal
neither
aid
smoke
importantli
modifi
dpp
iv
activ
bal
fluid
although
physiolog
substrat
dpp
iv
yet
formal
identifi
mani
import
peptid
includ
substanc
p
sever
cytokin
peptid
deriv
fiom
collagen
potenti
substrat
apn
ec
analog
express
monocyt
macrophag
granulocyt
intestin
pulmonari
hepat
renal
epitheli
tissu
endothelia
fibroblast
exopeptidas
releas
neutral
amino
acid
ntermin
end
peptid
function
postul
apn
modul
activ
peptid
tumor
invas
collagen
degrad
apn
express
regul
biolog
activ
peptid
state
cell
differenti
lymphocyt
appear
involv
induct
apn
monocyt
manner
similar
ace
cell
permiss
cytomegaloviru
infect
human
apn
shown
receptor
two
human
corona
virus
gastrointestin
tract
human
lung
fibroblast
bal
fluid
show
solubl
apn
activ
link
increas
proport
polymorphonuclear
cell
howev
actinonin
rel
specif
inhibitor
apn
could
complet
inhibit
hydrolysi
leupnitroanilid
bal
sampl
serum
sever
explan
postul
first
sever
enzym
act
substrat
differ
sensit
actinonin
inhibit
second
kinet
inhibitor
bind
enzym
may
complex
may
explain
incomplet
inhibit
third
hydrolysi
small
substrat
still
possibl
enzym
even
presenc
bound
inhibitor
present
approach
allow
us
differenti
possibl
detail
enzymat
analysi
would
necessari
answer
question
normal
volunt
popul
low
level
solubl
apn
dpp
iv
activ
could
detect
wherea
bronchial
alveolar
epitheli
cell
bronchoalveolar
macrophag
express
high
level
apn
howev
patholog
state
infecti
state
much
higher
amount
activ
enzym
present
solubl
form
epitheli
line
fluid
indic
shed
proteas
cell
membran
occur
diseas
specif
express
enzym
apn
dpp
iv
activ
may
origin
macrophag
epitheli
cell
well
endotheli
cell
wherea
juilleratjeanneref
aubert
leuenberg
ace
may
origin
macrophag
endotheli
cell
express
enzym
establish
howev
diseas
nonspecif
diffus
serum
exclud
conclus
result
demonstr
specif
aminopeptidas
carboxypeptidas
releas
solubl
enzym
high
amount
pulmonari
patholog
state
either
bronchoalveolar
structur
immunocompet
cell
bronchoalveolar
layer
observ
increas
express
enzym
measur
sampl
patholog
disord
limit
use
diagnost
tool
drug
abl
modul
apn
dpp
activ
addit
inhibitor
ace
activ
may
potenti
interest
studi
metabol
import
peptid
hormon
